Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2011 Oct 1;10(1):46–51. doi: 10.1016/j.cgh.2011.09.017

Figure 2.

Figure 2

One-way sensitivity analyses to determine the threshold at which monotherapy is favored over combination therapy for the probability of lymphoma (A), serious infection (B), and other SAE* (C). Expected QALYs are varied for combination therapy, while held constant for IFX monotherapy in these one-way analyses. *SAE other than serious infection.